Kawanami Daiji

カワナミダイジ | Kawanami Daiji

Affiliation and department：

Research field (1)： Metabolism and endocrinology

Research keywords (1)： diabetes, diabetic kidney disease, diabetic complications

Research theme for competitive and other funds (7)：

2023 - 2027 慢性腎臓病患者の健康寿命の延伸を目指した生体のリン感知機構の解明
2022 - 2025 Role of Rho-kinase in phosphate metabolism and diabetic kidney diseases
2022 - 2023 ペプチド医薬の超長期滞留性DDSの開発
2019 - 2022 Role of endothelial dysfunction in diabetic kidney disease
2016 - 2020 Regulation of Endothelial Function by mDia1

Show all

Papers (85)：

Kensuke Sekiguchi, Keiichiro Matoba, Yosuke Nagai, Satoru Nagao, Shinji Ohashi, Etsuko Mitsuyoshi, Takeshi Hayashi, Daiji Kawanami, Tamotsu Yokota, Hirotaka Shibata, et al. Rho-associated, coiled-coil-containing protein kinase 2 regulates expression of mineralocorticoid receptor to mediate sodium reabsorption in mice. Biochemical and Biophysical Research Communications. 2024. 150874-150874
Daisuke Yabe, Yoshiyuki Hamamoto, Daiji Kawanami, Rimei Nishimura, Yasuo Terauchi, Hanan Amadid, Uffe Christian Braae, Atheline Major-Pedersen, Ryo Suzuki. PIONEER REAL Japan: Primary results from a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice. Journal of Diabetes Investigation. 2024
Satoshi Miyamoto, Hiddo J.L. Heerspink, Dick de Zeeuw, Kota Sakamoto, Michihiro Yoshida, Masao Toyoda, Daisuke Suzuki, Takashi Hatanaka, Tohru Nakamura, Shinji Kamei, et al. A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope. Kidney International. 2024
Shunichiro Tsukamoto, Kazuo Kobayashi, Masao Toyoda, Atsuhito Tone, Daiji Kawanami, Daisuke Suzuki, Daisuke Tsuriya, Hideo Machimura, Hidetoshi Shimura, Hiromichi Wakui, et al. Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism. 2024
Yuichi Takashi, Daiji Kawanami, Seiji Fukumoto. Recent advances in fibroblast growth factor 23-related hypophosphatemic disorders. Current Opinion in Endocrinology, Diabetes & Obesity. 2024

ｍore...

MISC (80)：

川浪大治. 慢性腎臓病合併2型糖尿病におけるGLP-1受容体作動薬の腎アウトカム:日本からの展望. 新薬と臨床. 2024. 73. 8. 736-758
牟田芳美, 川浪大治. 乳酸アシドーシス. 月刊糖尿病. 2024. 16. 1. 33-38
川浪大治. 内科医からみた糖尿病網膜症. 日本糖尿病合併症. 2024. 38. 1. 42-45
川浪大治. 糖尿病性腎症における新規MR拮抗薬への期待と課題. 糖尿病学2024. 2024. 120-127
山本真悠子、川浪大治. Q. 血圧はいつも130 mmHg程度ですよ. それなのに血圧の薬を飲まないとだめですか?. 臨床雑誌「内科」特集患者さんからよく尋ねられる内科診療のQuestion. 2024. 133. 4. 982-984

ｍore...

Education (2)：

- 2004 東京慈恵会医科大学大学院医学研究科博士課程
- 1998 福岡大学医学部医学科

Professional career (1)：

博士(医学) (東京慈恵会医科大学)

Awards (11)：

2022/01 - 冲中記念成人病研究所研究助成
2021/10 - 第1回日本糖尿病学会キャリアデベロップメント報奨金
2019/12 - 臨床医学振興財団研究助成
2015/02 - 上原記念生命科学財団研究助成金
2014/11 - 第3 回万有医学奨励賞

Show all

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page